Abstract: The present disclosure provides methods and compositions for the treatment of cancer using an ACAT1 inhibitor in combination with an immune checkpoint inhibitor. The immune checkpoint inhibitor may inhibit the programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), lymphocyte-activation protein 3 (LAG-3), or combinations thereof. The ACAT1 inhibitor may be avasimibe, pactimibe, or purpactins, without limitation.
Type:
Grant
Filed:
January 11, 2017
Date of Patent:
February 27, 2024
Assignee:
Center for Excellence in Molecular Cell Science, Chinese Academy of Scienes
Abstract: A method of treating a patient having a cancer in which HER2, HER4, FGFR1, EPHA2 and/or FGFR3 is upregulated and/or in which HER2, HER4, FGFR1, EPHA2 and/or FGFR3 mediated-signaling is upregulated, the method comprising administering to the patient a compound comprising or consisting of an OPCML polypeptide (SEQ ID NO: 1), or a fragment thereof which comprises at least one Ig domain of OPCML, or a variant thereof having at least 90% sequence identity with the OPCML polypeptide or the fragment thereof, or a nucleic acid molecule which encodes the OPCML polypeptide or fragment or variant thereof.
Abstract: The present invention relates to a human or humanized antibody, or an antibody-based binding protein, modified antibody format retaining target binding capacity, antibody derivative or fragment retaining target binding capacity, which targets Receptor tyrosine kinase-like orphan receptor-1 (ROR1). It further relates to bi- or multispecific antibodies, to Immunoligand-Drug Conjugates, to Chimeric Antigen Receptors and to T-cells comprising such Chimeric Antigen Receptors.
Type:
Grant
Filed:
October 31, 2016
Date of Patent:
December 19, 2023
Assignee:
NBE-THERAPEUTICS AG
Inventors:
Lorenz Waldmeier, Ulf Grawunder, Roger Beerli
Abstract: The present invention relates to antibodies that specifically bind to B7-H4 (B7 Homology 4, encoded by gene VTCN1) and bispecific antibodies that specifically bind to both B7-H4 and CD3 (Cluster of Differentiation 3), and polynucleotides, pharmaceutical compositions and methods and uses thereof.
Type:
Grant
Filed:
July 16, 2021
Date of Patent:
December 12, 2023
Assignee:
Pfizer Inc.
Inventors:
James Reasoner Apgar, Andrea Therese Hooper, Malgorzata Agnieszka Nocula-Lugowska, Lei Wu
Abstract: An anti-PD-1/anti-VEGF natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof. Provided are a highly stable, heterodimeric form anti-PD-1/anti-VEGF bispecific antibody having natural IgG characteristics and free of mismatched heavy and light chains and preparation method for the antibody. The bispecific antibody is capable of simultaneously binding with two target molecules and provides improved efficacy in treating a complicated disease.
Abstract: Provided are HIV-1 fusion polypeptides, polynucleotides encoding such fusion polypeptides, vectors expressing such fusion polypeptides for use in eliciting an immune response against HIV-1; pharmaceutical and immunogenic compositions and kits comprising such fusion polypeptides, polynucleotides or vectors, and methods of use in treating and/or preventing HIV-1. Further provided are methods for design of antiviral vaccines, including vaccines to elicit an immune response against HIV-1.
Type:
Grant
Filed:
July 14, 2020
Date of Patent:
October 24, 2023
Assignee:
Gilead Sciences, Inc.
Inventors:
Xinan Liu, Azure T. Makadzange, Stephen R. Martin, Hesham Shehata, Evguenia Svarovskaia
Abstract: The disclosure relates to prostate neoantigens, polynucleotides encoding them, vectors, host cells, recombinant virus particles, vaccines comprising the neoantigens, proteinaceous molecules binding the prostate neoantigens, and methods of making and using them.
Type:
Grant
Filed:
January 9, 2020
Date of Patent:
October 24, 2023
Assignee:
Janssen Biotech, Inc.
Inventors:
Kurtis E. Bachman, Vipul Bhargava, Darryl L. Davis, Vinod Krishna, Guido Leoni, David Pocalyko, Pegah Safabakhsh, Manuel Sepulveda, Derick Siegel, Marco Gottardis
Abstract: The present invention relates to obinutuzumab (or its functional equivalents) for use in the treatment of a particular biomarker-defined DLBCL patient and a novel DLBCL patient subgroup, respectively. The present invention further relates to a method for treating DLBCL with obinutuzumab (or its functional equivalents) in a patient in need thereof, wherein said patient is a particular biomarker-defined DLBCL patient or belongs to a novel biomarker-defined DLBCL patient subgroup. The present invention further relates to the use of obinutuzumab (or its functional equivalents) for the preparation of a pharmaceutical composition for the treatment of DLBCL in the particular biomarker-defined DLBCL patient/novel DLBCL patient subgroup. The present invention further relates to a method for identifying a particular DLBCL patient/novel DLBCL patient subgroup and a method for diagnosing a novel form of DLBCL and a particular DLBCL patient/novel DLBCL patient subgroup, respectively.
Abstract: Provided are anti-claudin 18.2 (CLDN18.2) antibodies and fragments thereof. Also provided are isolated nucleic acid molecules that encode anti-CLDN18.2 antibodies, vectors comprising such nucleic acid, and host cells comprising such vectors or nucleic acids. Provided are methods of making anti-CLDN18.2. Also provided are related pharmaceutical compositions and methods using such pharmaceutical compositions in the treatment of disorders associated with aberrant CLDN18.2 expression, such as cancers.
Type:
Grant
Filed:
March 14, 2019
Date of Patent:
November 1, 2022
Assignee:
Beijing Xuanyi Pharmasciences Co., Ltd.
Inventors:
Yuntao Song, Yi Ding, Chen Dong, Zhiwei Li, John Lippincott, Ping Hui Szu
Abstract: The present disclosure relates to a HLA-G specific chimeric antigen receptor, a nucleic acid, a HLA-G specific chimeric antigen receptor expression plasmid, a HLA-G specific chimeric antigen receptor expressing cell, a pharmaceutical composition for treating cancer, and use of the HLA-G specific chimeric antigen receptor expressing cell. The chimeric antigen receptor specifically binds to human leukocyte antigen G. The nucleic acid encodes the HLA-G specific chimeric antigen receptor. The HLA-G specific chimeric antigen receptor expression plasmid expresses the HLA-G specific chimeric antigen receptor. The HLA-G specific chimeric antigen receptor expressing cell is obtained by transducing the HLA-G specific chimeric antigen receptor into an immune cell. The pharmaceutical composition for treating cancer includes the HLA-G specific chimeric antigen receptor expressing cell and a pharmaceutically acceptable carrier.
Abstract: The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer (e.g., a bladder cancer (e.g., UC, e.g., mUC), a kidney cancer, a lung cancer, a liver cancer, an ovarian cancer, a pancreatic cancer, a colorectal cancer, or a breast cancer). The invention is based, at least in part, on the discovery that expression levels of one or more biomarkers described herein in a sample from an individual having cancer can be used in methods of identifying an individual having a cancer who may benefit with an anti-cancer therapy that includes an immunotherapy (e.g., a PD-L1 axis binding antagonist such as an anti-PD-L1 antibody (e.g., atezolizumab)) and a suppressive stromal antagonist (e.g.
Type:
Grant
Filed:
May 5, 2020
Date of Patent:
October 18, 2022
Assignee:
Genentech, Inc.
Inventors:
Yinghui Guan, Yasin Senbabaoglu, Shannon Turley, Yulei Wang
Abstract: A vaccine containing an epitope of a heat shock protein 90 and uses thereof are disclosed. The epitope(s) of heat shock protein 90 has the amino acid sequence of SEQ ID NO: 1 and/or 2. A multi-epitope vaccine containing the epitope(s) and a method for treating or preventing cancer using the same are disclosed.
Abstract: The invention provides that OSTERIX (a.k.a. SP7) is a marker for gastrointestinal stem cells and that OSTERIX is expressed widely and at elevated levels in human gastrointestinal tumors.
Type:
Grant
Filed:
March 30, 2020
Date of Patent:
September 13, 2022
Assignee:
Rhode Island Hospital
Inventors:
Wentian Yang, Lijun Wang, Douglas C. Moore
Abstract: Described herein are novel anti-PD1 antibody reagents (e.g., antibodies, antigen-binding fragments thereof, and/or chimeric antigen receptors). Also described herein antibody-drug conjugates or kits comprising the disclosed antibody reagents, as well as methods of treating cancer by administering the disclosed antibody reagents.
Type:
Grant
Filed:
May 1, 2018
Date of Patent:
August 30, 2022
Assignee:
THE CHILDREN'S MEDICAL CENTER CORPORATION
Inventors:
Frederick W. Alt, Ming Tian, Hwei-Ling Cheng
Abstract: The present invention discloses an application of the exosome T?RII protein as a marker in preparing a breast cancer diagnostic kit, and belongs to the technology field of breast cancer detection kits. The present invention finds that the content of T?RII positive exosomes in the serum of breast cancer patients is significantly higher than these of healthy people, and after the surgery, the content of T?RII exosomes in the serum of breast cancer patients reduces significantly, which suggests the value of the T?RII positive exosomes during the diagnosis and prognosis of breast cancer. The present invention provides a breast cancer diagnosis kit based on detecting exosome T?RII protein in peripheral blood, which is simple in operation, and only needs to extract a small amount of peripheral blood of the test population, thereby detecting whether the test population has breast cancer and evaluating the tumor of the patient. The degree of malignancy and the state of metastasis.
Abstract: The present invention provides a method for evaluating tumorigenicity of a test cell, including transplanting the cell into anterior chamber of an eye of an experimental animal, and observing the presence or absence of tumor formation. According to the present invention, tumorigenicity can be evaluated in a short period and conveniently.
Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to an anthracycline drug moiety via a disulfide linker, anthracycline disulfide intermediates, and methods of using the antibody-drug conjugates.
Abstract: Described herein are compositions of matter and methods for treating cancer. The compositions comprise altered human telomerase polypeptides containing T cell epitopes that have been altered to increase immunogenicity. The methods comprise administration of the polypeptides or nucleic acids, such as DNA or RNA encoding the polypeptides, to individuals afflicted with, or at risk of, developing cancer.
Abstract: There is disclosed an improved ADC (antibody drug conjugate) type composition having at least two different drug payloads conjugated to a single targeting protein. More specifically, the present disclosure attaches a first drug conjugate to a dual Cysteine residue on a targeting protein and a second drug conjugate with a different drug to a Lys residue on the targeting protein.
Type:
Grant
Filed:
October 15, 2014
Date of Patent:
November 17, 2020
Assignee:
Sorrento Therapeutics, Inc.
Inventors:
Zhenwei Miao, Gang Chen, Tong Zhu, Alisher B. Khasanov, Yufeng Hong, Hong D. Zhang, Alexander Chucholowski
Abstract: In various embodiments, the present application teaches methods for tissue clearing in which tissues are rendered macromolecule-permeable and optically-transparent, thereby exposing their cellular structure with intact connectivity. In some embodiments, the present application teaches ePACT, which is a protocol for enhanced tissue clearing via expansion. In some embodiments, the present application teaches visualizing a tissue that has been expanded via ePACT.